Drummond Group provides complete EMR certification for Varian's ARIA software for radiation oncology

NewsGuard 100/100 Score

Varian Medical Systems (NYSE: VAR) today announced its ARIA® software for electronic medical records (EMR) and clinical practice management in radiation oncology has been certified for clinics that can now use it to qualify for federal funding under the U.S. HITECH Act.  

ARIA for radiation oncology (Version 11) received complete EMR certification for ambulatory environments from the Drummond Group.  Tested under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Testing and Certification Body (ONC-ATCB) program, the ARIA radiation oncology system was certified as 2011/2012 compliant in accordance with the criteria adopted by the U.S. Secretary of Health and Human Services.  Varian's ARIA for medical oncology practice management was similarly certified in May.

ARIA provides oncology clinics with software for managing the full spectrum of clinical, administrative, and financial activities.  It incorporates a comprehensive oncology-specific EMR that enables clinicians to design a personalized care path for each patient, from initial diagnosis through follow-up.  ARIA has been rated among the top three oncology IT solutions every year since 2008 by KLAS, an independent research firm that reports on the performance of healthcare vendors (http://www.klasresearch.com/).

"With this latest certification, both ARIA for medical oncology and ARIA for radiation oncology qualify as EMRs that can enable healthcare providers to seek financial incentives provided as part of the HITECH act," said Ken Hotz, a senior product manager at Varian.

Drummond Group's ONC-ATCB 2011/2012 certification program tests EMRs to determine if they meet the eligibility requirements to be considered a certified EMR under the HITECH Act. In turn, healthcare providers using the EMR systems of certified vendors are qualified to receive federal stimulus monies upon demonstrating meaningful use of the technology -- a key component of the federal government's push to improve clinical care delivery through the adoption and meaningful use of EMRs by U.S. healthcare providers.

To help ARIA users qualify for incentive payments under the HITECH Act, Varian has also launched a number of customer service programs, including Clinical Consulting Services and regularly-scheduled symposia and online webinars that cover how to use ARIA to demonstrate meaningful use of an EMR.

This Complete EMR is 2011/2012 compliant and has been certified by Drummond Group, an ONC-ATCB approved to certify any complete or modular EMR both ambulatory and inpatient, in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments.

ARIA for radiation oncology Version 11 was certified on July 14, 2011.  Certification ID number 04282011-1209-8 for Clinical Quality Measures: NQF0013, NQF0024, NQF0028, NQF0038, NQF0041, NQF0385, NQF0387, NQF0389, NQF0421. Additional software used: 7-Zip; MS Excel; Email software

SOURCE Varian Medical Systems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel treatment for polycythemia vera shows promise in clinical trial